Management of advanced adult soft tissue sarcoma.

Item

http://www.wikidata.org/entity/Q36674228

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Management of advanced adult soft tissue sarcoma.

@ast

Management of advanced adult soft tissue sarcoma.

@en

type

Item

label

Management of advanced adult soft tissue sarcoma.

@ast

Management of advanced adult soft tissue sarcoma.

@en

prefLabel

Management of advanced adult soft tissue sarcoma.

@ast

Management of advanced adult soft tissue sarcoma.

@en

P1476

Management of advanced adult soft tissue sarcoma.

@en

P2093

Vivien H C Bramwell

http://www.w3.org/2001/XMLSchema#string

P2860

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors.

High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults.

Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.

EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma.

Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

P304

43-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13577140310001607266

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51397814

http://www.w3.org/2001/XMLSchema#string

P698

18521368

http://www.w3.org/2001/XMLSchema#string

P932

2395519

http://www.w3.org/2001/XMLSchema#string